- Home
- RLX vs CDNA Comparison
RLX vs CDNA Comparison
Compare RLX & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLX | CDNA |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | RLX | CDNA |
|---|---|---|
| Price | $1.69 | $63.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $2.50 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 3.0M | 1.1M |
| Earning Date | 05-15-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.13 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $55.89 | $16.01 |
| Revenue Next Year | $15.07 | $11.31 |
| P/E Ratio | ★ $28.09 | $28.81 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $1.67 | $13.95 |
| 52 Week High | $2.68 | $63.09 |
Technical Indicators
Market Signals| Indicator | RLX | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 35.08 | 78.93 |
| Support Level | $1.67 | $17.26 |
| Resistance Level | $2.08 | N/A |
| Average True Range (ATR) | 0.04 | 2.71 |
| MACD | 0.00 | 0.78 |
| Stochastic Oscillator | 25.00 | 93.63 |
Price Performance
Historical ComparisonAbout RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market. The company has two reportable segments, Core Markets and Europe Acquisition. The majority of the revenue is earn from Core Markets segment.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.